
Lonza Group Ltd
Swiss-listed contract development and manufacturing organization, one of the world's largest CDMOs, headquartered in Basel with roots in Visp since 1897.
Company Type
public
Founded
1897
Headquarters
Basel, Switzerland
Revenue
CHF 6.531 billion (FY2025); CORE EBITDA CHF 2.064 billion
Employees
approximately 19,900 (FY2025)
Primary Market
Global
Shop Lonza Group Ltd Brands
Disclosure: We may earn commission from purchasesAbout Lonza Group Ltd
What is Lonza Group?
It is a Swiss contract development and manufacturing organization, one of the world's largest, producing biologics, small molecules, and advanced therapies for pharmaceutical and biotech customers.
Is Lonza publicly traded?
Yes. It trades on the SIX Swiss Exchange under LONN as a Swiss Market Index constituent, with a secondary listing on the Singapore Exchange.
Who owns Lonza Group?
Its public shareholders. No single controlling owner exists; major institutional holders include BlackRock and Baillie Gifford.
How much revenue does Lonza make?
FY2025 sales were CHF 6.531 billion, with CORE EBITDA of CHF 2.064 billion at a 31.6 percent margin.
Where is Lonza headquartered?
In Basel, Switzerland, since 2022. Its founding and largest site remains Visp in the canton of Valais.
What are Lonza's business platforms?
Integrated Biologics, Advanced Synthesis, and Specialized Modalities, covering biologics, small molecules, cell and gene therapies, and emerging formats.
History of Lonza Group Ltd
Lonza was founded in 1897 in Visp, Valais, as an electrochemical venture exploiting the region's hydroelectric power, taking its name from the local river. Its first century built a diversified chemical business spanning basic chemicals, intermediates, and eventually specialty products and life sciences ingredients.
Internationalization and listing defined the modern era. Lonza went public on the SIX Swiss Exchange in 1999, then used the following two decades to shift decisively into life sciences, building leading positions in mammalian cell culture, biologics development, and contract manufacturing. Acquisitions such as Cambrex's biopharma business and Capsugel broadened the platform.
The decisive pivot came in 2019, when Lonza sold its Specialty Ingredients division to Bain Capital and Cinven for $4.7 billion, exiting the last major non-pharma operation and becoming a pure healthcare CDMO. The capsule business followed out in 2025. In 2024 it acquired Roche's Vacaville, California biologics facility for $1.2 billion, expanding its largest-product manufacturing base, and continued major investments at Visp.
The headquarters moved to Basel in 2022, placing the corporate center inside Switzerland's pharma cluster while Visp stayed the industrial heart. FY2025 results showed the strategy working: sales reached CHF 6.531 billion, up strongly on the prior year, with a 31.6 percent CORE EBITDA margin, driven by demand for biologics, ADCs, and high-growth modalities.
Lonza Group Ltd Sustainability & Ethics
Lonza publishes annual sustainability reporting as part of its disclosure obligations, covering environmental footprint of its manufacturing network, decarbonization targets, and social indicators across its global workforce. Its Visp site, hydro-powered at origin, anchors a renewable energy narrative that predates modern ESG frameworks.
As an SMI constituent it complies with Swiss governance and reporting requirements including remuneration disclosure and non-financial reporting, and it operates under the regulatory scrutiny inherent to FDA and EMA-audited pharmaceutical manufacturing.
Brands Owned by Lonza Group Ltd
Lonza Group Ltd owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Lonza Group Ltd
public · Founded 1897 · Basel, Switzerland
1
brands
Lonza Group Ltd Ownership: Pros & Cons
Advantages
- +Global top-two CDMO position with benchmark status in biologics
- +Pure-play life sciences focus after completed divestitures
- +31.6 percent margin demonstrating structural pricing power
- +Secular growth in pharmaceutical outsourcing
Considerations
- -Heavy capital intensity to sustain capacity leadership
- -Exposure to biotech funding cycles at the development end
- -Asian competitors expanding aggressively in biologics
- -Swiss franc reporting versus dollar and euro revenue
Frequently Asked Questions About Lonza Group Ltd
What is Lonza Group?
It is a Swiss contract development and manufacturing organization, one of the world's largest, producing biologics, small molecules, and advanced therapies for pharmaceutical and biotech customers.
Is Lonza publicly traded?
Yes. It trades on the SIX Swiss Exchange under LONN as a Swiss Market Index constituent, with a secondary listing on the Singapore Exchange.
Who owns Lonza Group?
Its public shareholders. No single controlling owner exists; major institutional holders include BlackRock and Baillie Gifford.
How much revenue does Lonza make?
FY2025 sales were CHF 6.531 billion, with CORE EBITDA of CHF 2.064 billion at a 31.6 percent margin.
Where is Lonza headquartered?
In Basel, Switzerland, since 2022. Its founding and largest site remains Visp in the canton of Valais.
What are Lonza's business platforms?
Integrated Biologics, Advanced Synthesis, and Specialized Modalities, covering biologics, small molecules, cell and gene therapies, and emerging formats.






